


**ABSTRACT**

A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is unsubstituted, mono-, di- or tri-substituted (C<sub>3</sub>-C<sub>11</sub>)cycloalkyl or (C<sub>3</sub>-C<sub>11</sub>)cycloalkenyl or the like, A is unsubstituted (C<sub>1</sub>-C<sub>7</sub>)alkyl or (C<sub>2</sub>-C<sub>5</sub>)alkenyl, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy-(C=O), or unsubstituted, mono-, di- or tri- substituted aryl, or aromatic-heterocyclic or the like, M is a covalent bond O, S, NH or the like, Y is 4- to 12-membered bicyclic-carbocyclic rings or 4- to 12-membered bicyclic-heterocyclic rings, or 5- to 17 membered spirocarbocyclic rings or 5- to 17-membered spiroheterocyclic rings or the like, Z<sup>1</sup>, Z<sup>2</sup>, Z<sup>3</sup> and Z<sup>4</sup> are hydrogen or the like, is disclosed. These compounds have ORL1-receptor agonist activity, and are thus useful as analgesics or the like in mammalian subjects.

RECEIVED  
U.S. PATENT AND TRADEMARK OFFICE

EXPRESS MAIL NO. EL 162 814 379 US